Ablynx NV, a late-stage clinical biopharmaceutical company, develops treatments for a range of therapeutic indications. The company develops Nanobodies that are proprietary therapeutic proteins based on single-domain antibody fragments for the treatment of inflammation, hematology, immuno-oncology, oncology, and respiratory diseases. Its clinical programs include caplacizumab, an anti-von Willebrand Factor Nanobody that has completed Phase III clinical trial to treat acquired thrombotic thrombocytopenic purpura; ALX-0171, which is in Phase IIb clinical trial for the treatment of respiratory syncytial virus infection; and Vobarilizumab, an anti-IL-6R Nanobody that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis, as well as in Phase II clinical trial to treat systemic lupus erythematosus. The company also develops ALX-0761, which is in Phase Ib clinical trial for the treatment of psoriasis, as well as various auto-immune disorders; Anti-VEGF/Ang2 Nanobody that is in Phase I clinical trial for patients with solid tumors; Anti-CX3CR1 Nanobody, which is in Phase I clinical trial for treating chronic kidney diseases; ozoralizumab, which has completed Phase I/IIa clinical trial for the treatment of auto-immune disorders with focus on rheumatoid arthritis; and ALX-0141, a trivalent Nanobody for the treatment of bone-loss related disorders comprising osteoporosis and bone metastasis, as well as completed a Phase I study in post-menopausal women. Ablynx NV has collaboration and alliance agreements with Merck & Co., Inc., AbbVie, Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Eddingpharm, Novo Nordisk A/S, Novartis Pharma AG, Taisho Pharmaceutical Co., Ltd., and Sanofi S.A. The company was formerly known as MatchX and changed its name to Ablynx NV in June 2002. Ablynx NV was founded in 2001 and is headquartered in Ghent, Belgium.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:ABLYF
CUSIPN/A
Phone329-262-0000
Debt
Debt-to-Equity Ratio0.86
Current Ratio7.07
Quick Ratio7.07
Price-To-Earnings
Trailing P/E Ratio-25.70
Forward P/E Ratio-44.81
P/E GrowthN/A
Sales & Book Value
Annual Sales$62.73 million
Price / Sales60.74
Cash FlowN/A
Price / CashN/A
Book Value$2.71 per share
Price / Book18.68
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees438
Outstanding Shares75,250,000
Ablynx (OTCMKTS:ABLYF) Frequently Asked Questions
What is Ablynx's stock symbol?
Ablynx trades on the OTCMKTS under the ticker symbol "ABLYF."
When is Ablynx's next earnings date?
What price target have analysts set for ABLYF?
1 Wall Street analysts have issued 12-month price targets for Ablynx's shares. Their predictions range from $26.00 to $26.00. On average, they anticipate Ablynx's share price to reach $26.00 in the next twelve months. View Analyst Ratings for Ablynx.
Who are some of Ablynx's key competitors?
Some companies that are related to Ablynx include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), argenx (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA) and Repligen (RGEN).
Who are Ablynx's key executives?
Ablynx's management team includes the folowing people:
- Dr. Edwin Moses, Chief Exec. Officer and Director (Age 64)
- Mr. Wim Ottevaere, Chief Financial Officer (Age 62)
- Mr. Piet Houwen, Chief Operations Officer
- Dr. Robert Friesen Ph.D., Chief Scientific Officer
- Lies Vanneste, Director of Investor Relations
Has Ablynx been receiving favorable news coverage?
Media headlines about ABLYF stock have trended positive recently, according to Accern. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ablynx earned a news impact score of 0.43 on Accern's scale. They also assigned news coverage about the company an impact score of 48.26 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Ablynx?
Shares of ABLYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ablynx's stock price today?
One share of ABLYF stock can currently be purchased for approximately $50.63.
How big of a company is Ablynx?
Ablynx has a market capitalization of $3.81 billion and generates $62.73 million in revenue each year. The company earns $-122,670,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. Ablynx employs 438 workers across the globe.
How can I contact Ablynx?
Ablynx's mailing address is TECHNOLOGIEPARK 21 ZWIJNAARDE, GHENT C9, 9052. The company can be reached via phone at 329-262-0000.
MarketBeat Community Rating for Ablynx (ABLYF)
MarketBeat's community ratings are surveys of what our community members think about Ablynx and other stocks. Vote "Outperform" if you believe ABLYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABLYF will underperform the S&P 500 over the long term. You may vote once every thirty days.
